Black Diamond Therapeutics, Inc. - Common Stock (BDTX)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 59% below Graham Number ($4.51) — significant margin of safety
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 27.3% — good return on equity
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $105 million . Key value metrics: P/E ratio 3.7, P/B ratio 1.01, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Black Diamond Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) is trading 59% below its Graham Number of $4.51 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 3.7x.
On financial health, BDTX shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 27.3% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.25.
StockPik's composite Value Score for BDTX is 100/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BDTX shows earnings growing at 132%.